---
company: Sionna Therapeutics, Inc.
ticker: SION
form: 8-K
filed: 2026-11-10
accepted: 2026-11-10T12:05:46+00:00
accession: 0001628280-26-072497
source: https://www.sec.gov/Archives/edgar/data/2036042/000162828026072497/
quarterly_report: https://www.sec.gov/Archives/edgar/data/2036042/000162828026072499/
---

# Sionna Therapeutics (SION) Q3 2026 earnings

## Header

- Company: Sionna Therapeutics, Inc.
- Reported: 2026-11-10 07:05 BMO ET
- Source: 8-K only — accession 0001628280-26-072497, Item 2.02 + Exhibit 99.1
- Verdict: Net loss widened to $32.4 million as R&D and G&A expenses increased, offset by a 46% workforce reduction that extended cash runway to the second half of 2029.

## Headline numbers

not stated in the 8-K

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $34.8M (+38% YoY)
- One-offs in the quarter: Restructuring costs associated with workforce reduction
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: not stated in the 8-K

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---:|---|---:|
| Cash runway | Second half of 2029 | 2028 | — | +1.5 years |
| Workforce reduction | 46% | — | — | — |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: No revenue reported.
- EPS story: Net loss per share increased due to higher operating expenses and a wider net loss.
- One-off check: Restructuring costs associated with workforce reduction

## The good

- Cash runway extended to the second half of 2029 following workforce reduction

## The bad

- Net loss widened to $32.4 million
- G&A expenses increased 20.8% sequentially

## The ugly

- SION-719 PreciSION CF Phase 2a trial did not achieve its key activity endpoint, leading to discontinuation of the program

## Open questions

- How will the AscenSION CF Phase 2 proof-of-concept trial design incorporate learnings from PreciSION CF related to dosing adherence and sweat chloride variability?
- What specific clinical benefits are anticipated from the SION-451 + SION-2222 dual combination in the AscenSION CF trial?

## Full release

### Sionna Therapeutics (SION) earnings release, November 10, 2026

Sionna Therapeutics, Inc. (SION) · Form 8-K, Item 2.02 · Filed 2026-11-10 · [SEC filing](https://www.sec.gov/Archives/edgar/data/2036042/000162828026072497/)

Sionna Therapeutics Reports Third Quarter 2026 Financial Results

Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027

Clinical and nonclinical data presented at 2026 NACFC support advancement of SION-451 + SION-2222 and the potential of NBD1 stabilizer combinations to benefit a broad population of people with CF

Strong cash position of $249.8 million as of September 30, 2026, expected to fund operations into the second half of 2029

WALTHAM, Mass., Nov 10, 2026 (GLOBE NEWSWIRE) – Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination,” said Mike Cloonan, President and Chief Executive Officer of Sionna. “We believe the findings from the PreciSION CF post hoc analyses, together with the dual combination’s favorable Phase 1 results, support advancing the dual combination into the next phase of development. With our resources focused on developing this program and cash runway expected into the second half of 2029, we are well-positioned to execute our strategy to deliver new treatment options for people with CF.”

Pipeline Updates

• SION-451 + SION-2222 Dual Combination Advancing into AscenSION CF Phase 2 proof-of-concept:

Sionna plans to initiate the AscenSION CF Phase 2 proof-of-concept (POC) trial in the first quarter of 2027. SION-451 is an NBD1 stabilizer and SION-2222 (galicaftor) is a transmembrane domain 1 (TMD1)-directed CFTR corrector. The open-label trial will evaluate participants with CF homozygous for F508del treated with SION-451 + SION-2222 for 28 days after switching from Trikafta®. The trial will assess sweat chloride, safety, and pharmacokinetics (PK), and its design will incorporate key learnings from PreciSION CF related to dosing adherence and sweat chloride variability. SION-451 + SION-2222 was selected as the dual combination based on the totality of the clinical, PK, and nonclinical data, including achievement of the safety, tolerability, and PK objectives in the Phase 1 healthy volunteer trial.

• Completed Comprehensive Analysis of SION-719 PreciSION CF:

As previously announced, the PreciSION CF Phase 2a trial of SION-719 added to Trikafta did not achieve its key activity endpoint, and Sionna is not advancing SION-719 as an add-on to standard of care. Post hoc analyses excluding three participants with drug exposures consistent with dosing non-adherence showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L when SION-719 was added to Trikafta, which Sionna believes is indicative of NBD1 biological activity. The analyses also identified other potential confounding factors related to the complex interaction of SION-719 combined with Trikafta that may have blunted the additional benefit of NBD1 stabilization. These findings, together with results from the Phase 1 dual combination trial, informed the decision to advance SION-451 + SION-2222 and the design of the AscenSION CF trial.

• Presented Clinical and Nonclinical Data at 2026 North American Cystic Fibrosis Conference:

In October 2026, Sionna presented clinical and nonclinical data in an oral presentation and poster at the North American Cystic Fibrosis Conference (NACFC) in Atlanta, Georgia. The oral presentation summarized the previously disclosed post hoc analyses of PreciSION CF and the rationale for advancing SION-451 + SION-2222 into AscenSION CF. The poster evaluated the effects of Sionna’s NBD1 stabilizers, SION-451 and SION-719, in combination with complementary CFTR modulators, including SION-2222 and SION-109, in primary CF human bronchial epithelial cells from donors with either two copies of F508del or one copy of F508del and a null CFTR mutation. Across both donor groups, the NBD1 stabilizer-based combinations demonstrated improved CFTR trafficking and function up to wild-type levels, supporting their potential to benefit a broad population of people with CF.

Corporate Update

• Implemented Workforce Reduction and Cost-Saving Measures:

In

September 2026, following a comprehensive review of its operations, Sionna implemented a workforce reduction of approximately 46% and other cost-saving measures to focus resources on advancing SION-451 + SION-2222 and extend its operating runway.

Financial Results for the Quarter Ended September 30, 2026

Research and Development Expenses:

Research and development expenses were $22.0 million for the third quarter of 2026, compared to $16.0 million for the third quarter of 2025. This increase was primarily driven by development expenses incurred during the period, personnel-related costs, including stock-based compensation expenses, and restructuring related costs associated with the workforce reduction.

General and Administrative Expenses:

General and administrative expenses were $12.8 million for the third quarter of 2026, compared to $7.8 million for the third quarter of 2025. This increase was primarily due to personnel-related costs, including stock-based compensation expenses, and restructuring related costs associated with the workforce reduction.

Net Loss:

Net loss was $32.4 million for the third quarter of 2026, compared to a net loss of $20.3 million for the third quarter of 2025.

Cash and Cash Equivalents:

Cash, cash equivalents and marketable securities totaled $249.8 million as of September 30, 2026. Sionna expects its current cash position to fund operations into the second half of 2029.

About Sionna Therapeutics... (truncated)y developing novel medicines that improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking meaningful improvements in clinical outcomes and quality of life for people with CF. For more information about Sionna, visit www.sionnatx.com.

Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Sionna’s beliefs and expectations regarding: its goal of transforming the treatment paradigm for CF and providing clinically meaningful benefit for people with CF; the potential of Sionna’s product candidates, including the SION-451 + SION-2222 dual combination, to expand therapeutic options for people with CF, including the potential of NBD1 stabilizer combinations to benefit a broad population of people with CF; Sionna’s interpretation of the results of the PreciSION CF trial and the impact of potential confounding factors on the interpretation of those results; the potential for NBD1 stabilization to improve CFTR function and produce clinical benefit, including beliefs about NBD1 biological activity in PreciSION CF and the translatability of preclinical and in vitro assay data to clinical outcomes; the objectives, design, timing, initiation and conduct of the AscenSION CF Phase 2 proof-of-concept trial of SION-451 + SION-2222; the therapeutic potential, clinical benefits and safety of SION-451 + SION-2222; the ability of clinical trials to demonstrate safety and efficacy of Sionna’s product candidates; the ability of Sionna’s nonclinical studies or earlier clinical trials, including post hoc analyses of the PreciSION CF trial, to predict later clinical trial results; the expected benefits of Sionna’s workforce reduction and other cost-saving measures, including the ability to focus resources on advancing SION-451 + SION-2222 and to extend its operating runway; and financial projections and expectations regarding the time period in which Sionna’s capital resources will be sufficient to fund its anticipated operations, including cash runway, use of capital, expenses and other financial results. In some cases, the forward-looking statements can be identified by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties inherent in the development of product candidates, including uncertainties concerning the initiation, timing, progress, and results of Sionna’s ongoing, planned and future clinical trials and studies; uncertainties in interpreting the PreciSION CF results and potential confounding factors; the inherent limitations of post hoc analyses, which are exploratory and may not reliably predict future outcomes; the risk that in vitro and preclinical data may not translate to clinical benefit; the risk that results observed with one compound may not be predictive of results with a different compound or combination; uncertainties in designing and conducting the AscenSION CF Phase 2 trial; Sionna's ability to replicate positive results from earlier nonclinical studies or clinical trials, or results of post hoc analyses thereof, in current or future clinical trials; Sionna’s ability to demonstrate that its NBD1 stabilizers, complementary CFTR modulators, and any potential future product candidates are safe and effective for their proposed indications; the ability to obtain regulatory feedback or approvals; the ability to achieve anticipated restructuring savings and runway extension; the ability to retain key personnel and capabilities following the workforce reduction; the ability to secure sufficient funding; regulatory developments in the United States and foreign countries; the competitive landscape for CF treatments, including existing therapies; and general economic, industry and market conditions. These risks and uncertainties are described in the section entitled “Risk Factors” in Sionna’s most recent

Annual Report on Form 10-K as well as any subsequent filings with the Securities and Exchange Commission. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. In addition, any forward-looking statements represent Sionna’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Sionna explicitly disclaims any obligation to update any forward-looking statements except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor & Media Contact

Juliet Labadorf ir@sionnatx.com media@sionnatx.com

#### Financial statements

##### Income Statement (media@sionnatx.com (In thousands, except per share data))

| | Sionna Therapeutics, Inc. – Consolidated Statements of Operations – (Unaudited) – Three Months Ended – September 30, – 2026 | Sionna Therapeutics, Inc. – Consolidated Statements of Operations – (Unaudited) – Nine Months Ended – September 30, – 2026 |
|---|---:|---:|
| **Operating expenses:** | | |
| Research and development | 22,025 | 62,852 |
| **Total other income** | | |
| Net loss | -32,418 | -89,083 |
| Net loss per share, basic and diluted | -0.72 | -1.98 |

##### Balance Sheet (media@sionnatx.com (in thousands))

| | Sionna Therapeutics, Inc. – Selected Consolidated Balance Sheet Data – (Unaudited) – September 30, – 2026 | Sionna Therapeutics, Inc. – Selected Consolidated Balance Sheet Data – (Unaudited) – December 31, – 2025 |
|---|---:|---:|
| Cash, cash equivalents, and marketable securities | 249,797 | 310,302 |

##### Cash Flow (From the 10-Q · Nine Months Ended September 30, — (Unaudited))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| **Cash flows from operating activities:** | | |
| Net loss | -89,083 | -54,828 |
| **Adjustments to reconcile net loss to net cash used in operating activities:** | | |
| Stock-based compensation expense | 20,479 | 8,240 |
| Non-cash operating lease expense | 1,470 | 1,471 |
| Amortization of discount on marketable securities | -566 | -2,699 |
| Depreciation expense | 463 | 495 |
| **Changes in operating assets and liabilities:** | | |
| Prepaid expenses and other current assets | 1,596 | -543 |
| Accounts payable | 281 | 295 |
| Accrued expenses and other current liabilities | 4,207 | -517 |
| Operating lease liabilities | -1,630 | -1,585 |
| Net cash used in operating activities | -62,783 | -49,671 |
| **Cash flows from investing activities:** | | |
| Purchases of property and equipment |  | -173 |
| Purchases of marketable securities | -69,712 | -282,147 |
| Maturities of marketable securities | 154,947 | 140,983 |
| Net cash provided by (used in) investing activities | 85,235 | -141,337 |
| **Cash flows from financing activities:** | | |
| Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period |  | 202,071 |
| Payment of deferred offering costs | -583 |  |
| Exercise of common stock options | 3,558 | 1,980 |
| Net cash provided by financing activities | 2,975 | 204,051 |
| Net increase in cash, cash equivalents and restricted cash | 25,427 | 13,043 |
| Cash, cash equivalents and restricted cash at beginning of period | 59,414 | 38,750 |
| Cash, cash equivalents and restricted cash at end of period | 84,841 | 51,793 |
| **Supplemental disclosure of non-cash investing and financing activities:** | | |
| Conversion of convertible preferred stock into common stock upon closing of initial public offering |  | 330,368 |
| Offering costs transferred to additional paid in capital |  | 4,265 |
